title: [Systemic chemotherapy and breast cancer].
abstract: Breast cancer mortality is decreasing, partly due to better adjuvant treatments with new drugs and new schedules. In Belgium, the overall survival is 76%. Chemotherapy is still an important treatment option. We need to better select patients who really will benefit from treatment in order to decrease toxicity and improve long term outcome.Targeting the specific population is now a priority. Prognostic and predictive factors will enable us to better define the sub-population of patients most benefiting from treatment. We will also discuss the knowledge of systemic treatment. When we have to decide wether chemotherapy is indicated, we need to well balance the treatment risks and benefits because gain in survival is important but reducing short and long term toxicity is also a challenge.
authors.affiliation: Service d'Oncologie Médicale, CHU de Liège, Belgique. joelle.collignon@chu.ulg.ac.be
authors.forename: J
authors.initials: J
authors.lastname: Collignon
authors.forename: A
authors.initials: A
authors.lastname: Rorive
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: C
authors.initials: C
authors.lastname: Andre
authors.forename: S
authors.initials: S
authors.lastname: Maweja
authors.forename: E
authors.initials: E
authors.lastname: Lifrange
authors.forename: P
authors.initials: P
authors.lastname: Coucke
authors.forename: G
authors.initials: G
authors.lastname: Jerusalem
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents